title: [Use of systemic immunomodulator xymedone in distructive pulmonary tuberculosis].
abstract: The study was undertaken to examine 59 patients with destructive pulmonary tuberculosis who had T-cell dysfunction (loss of CD3+, CD4+, lymphocytes, slightly positive tuberculin test) and augmented IgA and IgG production. Oral Xymedone given in a dose 2.0 g daily for two 2 months in combination with antibacterial therapy abolished lymphopenia, restored CD4+ counts, CD4+/CD3+ ratio, upregulated IgG levels, but did not affect IgA levels. The Xymedone-treated patients developed fewer side effects due to basic antibacterial chemotherapy and showed more rapid culture conversion, resolution of pulmonary infiltration and closure of destructive cavities.
authors.forename: Iu D
authors.initials: IuD
authors.lastname: Slabnov
authors.forename: A A
authors.initials: AA
authors.lastname: Vizel'
authors.forename: G V
authors.initials: GV
authors.lastname: Cherepnev
authors.forename: O V
authors.initials: OV
authors.lastname: Firsov
authors.forename: L A
authors.initials: LA
authors.lastname: Sabirova
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D017252:CD3 Complex / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007070:Immunoglobulin A / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage*; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D017252:CD3 Complex; D015704:CD4 Antigens; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011743:Pyrimidines; C069705:xymedon